drugset / Trial / NCT02305030

Effect of Opicapone at Steady State on Warfarin Pharmacokinetics

NCT02305030

Phase 1 Completed 20 enrolled Bial - Portela C S.A.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Single-centre, open-label, fixed-sequence design consisting of 2 periods separated by a washout period of at least 14 days.

Timeline

Start
2014-03
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Opicapone Small molecule 50 mg
Subject Warfarin Small molecule 25 mg

Indications